Browse complete Report Men’s Health Therapeutics Market to 2016 – Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors Will Dominate the Market
Browse all GBI Research Market Research Reports
GBI Research has released its pharmaceutical industry research “Men’s Health Therapeutics Market to 2016 – Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors will Dominate the Market”. The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global men’s health market. The report analyzes the markets for men’s health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
GBI Research finds that the men’s health market will continue to grow moderately. The prime reason for stagnancy will be the patent expiry of a top selling blockbuster, Viagra. The overall men’s health market is driven by the launch of late-stage pipeline candidates and the steady increase in prevalence and prescription population. The erectile dysfunction market controls a major portion of the men’s health market. In 2009 it accounted for 81% of the total men’s health market. Male hypogonadism accounts for 18% of the total market size. The premature ejaculation market represents a small portion of the total men’s health market. The premature ejaculation market has the highest level of unmet needs because it does not have any FDA approved products. However, it will grow at a higher rate during the forecast period compared to the erectile dysfunction and male hypogonadism market. This is because the premature ejaculation market will see the launch of new drugs in the near future. In 2009, the global men’s health market was estimated at $4,019m.
Scope
- Annualized market data for the men’s health market from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including erectile dysfunction, male hypogonadism and premature ejaculation.
- Analysis of the men’s health market in the leading geographies of the world, which include the US (United States), the UK (United Kingdom), Germany, France, Italy, Spain and Japan.
- Market characterization of the men’s health market, including market size, annual cost of therapy, sales volume and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Inc., Abbott Laboratories, Endo-Pharmaceuticals Holding Inc., Janssen-Cilag EMEA, VIVUS Inc., Auxilium Pharmaceuticals, Inc., APP Pharmaceuticals, Inc, Columbia Laboratories, Inc., Watson Pharmaceuticals, Inc. and Valeant Pharmaceuticals International.
- Key M&A activities, licensing agreements, that have taken place in 2009 in the global men’s health market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Original Source: Men’s Health Therapeutics Market
Buy Now: Market Research
